NGS

Disease-Focused Next Generation Sequencing (NGS)

Testing for somatic (acquired) gene mutations can help better understand a range of blood and solid tumor cancers. While insights continue to uncover new gene associations and their impact across the continuum of patient care, especially in treatment selection, siParadigm provides panels that deliver the most actionable and relevant information for clinicians.

Solid Tumor Panels

NSCLC and CRC NGS Panel (22 Genes)

ALK
AKT1
BRAF
CTNNB1
DDR2
EGFR
ERBB2
ERBB4
FBX7
FGFR1
FGFR2
FGFR3
KRAS-Extended
MAP2K1
MET
NOTCH1
NRAS
PTEN
PIK3CA
STKI1
SMAD4
TP53

Hereditary Cancer Assessment Panel

BRCA1
BRCA2

Hematology Panels

AML Panel (19 Genes)

ASXL1
BRAF
CBL
CEBPA
DNMT3A
FLT3
GATA2
IDH1
IDH2
JAK2
KIT
KRAS
NPM1
NRAS
PTPN11
RUNX1
TET2
TP53
WT1

CLL Panel (17 Genes and Targeted Regions)

ATM
(exons 2-63)
BTK
(exons 14-16)
BIRC3
(exons 6-8)
CARD11
(exons 2-8)
CD79B
(exons 4-5)
DDX3X
(exons 7-9, 11, 14)
FBXW7
(exons 6-9)
MAPK1
(exon 7)
MYD88
(exons 3-5)
NOTCH1
(hotspots)
PIK3CA
(hotspots)
PIK3CD
(hotspots)
PTEN
(hotspots)
PTPN6
(hotspots)
SF3B1
(hotspots)
TP53
(exons 2-11)
XPO
(exons 12, 13, 15)

CMML Panel (18 Genes)

ASXL1
CBL
CSF3R
DNMT3A
EZH2
JAK3
KRAS
MPL
NOTCH1
NRAS
RUNX1
SETBP1
SF3B1
SRSF2
TET2
TP53
U2AF1
ZRSR2

MDS Panel (19 Genes)

ASXL1
DNMT3A
ETV6
EVI1
EZH2
IDH1
IDH2
KDM6A/UTX
KRAS
NRAS
RPS14
RUNX1
SETBP1
SF3B1
SRSF2
TET2
TP53
U2AF1
ZRSR2

MPN Panel (16 Genes)

ASXL1
CALR
CSF3R
DNMT3A
EZH2
JAK2
JAK3
IDH1
IDH2
MPL
NRAS
SH2B3
SETBP1
SRSF2
TET2
TP53

Pan-Myeloid Panel (43 Genes)

ASXL1
BRAF
CALR
CBL
CDK2NA
CEBPA
CSF1R
CSF3R
DNMT3A
ETV6
EVI1
EZH2
FBXW7
FGFR1
FGFR2
FGFR3
FLT3
GATA2
IDH1
IDH2
JAK2
JAK3
KDM6A/UTX
KIT
KRAS
MPL
MYD88
NOTCH1
SNPM1
NRAS
PDGFRA
PTPN11
RPS14
RUNX1
SETBP1
SF3B1
SH2B3
SRSF2
TET2
TP53
U2AF1
WT1
ZRSR2

"While we have many laboratories to choose from, we consider siParadigm to be the most reliable. Contact with a hematopatholgist is rapid and informative."

Barry Kaplan, MD, PhD
Oncologist/Hematologist, Queens Medical Assoc.

Discover more.

A Model Experience

With core values rooted in service and integrity, our leadership team sets the bar high.

We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.

Patient-Friendly Billing

All billing is treated as in-network regardless of insurance company.

Patients are only responsible for payments according to their in-network benefit program, co-insurance and/or deductible for laboratory services.

Accredited and Certified

siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).

We also hold select state licensure where required.